

The 9th International Advanced Course on Vaccinology in Asia Pacific Regions

IVI, Seoul, May 11-16, 2009

DRAFT AGENDA

DAY 1: Monday, May 11, 2009

900 930 Welcome address and IVI introduction J Clemens

EPIDEMIOLOGY

Chairperson:

930 1030 Observational methods in vaccine evaluation A Lopez TAB 1
 1030 1045 Coffee break
 1045 1215 Periods and measures of transmissibility J Kuritsky TAB 2
 1215 1330 Lunch
 1330 1400 Vaccines and disease control, elimination, and eradication J Partridge TAB 3
 1400 1430 Surveillance: definition, goals, and methodology M Favorov TAB 4
 1430 1500 Ethical principles and review P Kilgore TAB 5
 1500 1515 Coffee break

IMMUNOBIOLOGY

Chairperson:

1515 1600 Vaccine concepts: immunological basis C Czerkinsky TAB 6
 1600 1645 Basic principle of immune responses: innate versus adaptive immunity H Kiyono TAB 7
 1730 2000 **Welcome reception** at the IVI Lobby

DAY 2: Tuesday, May 12, 2009

MOVING FROM DISCOVERY TO LICENSED PRODUCT

Chairperson:

830 900 Antigen delivery systems (adjuvants, DNA-based vaccines, recombinant viral vaccines) M Liu TAB 8
 900 930 Vaccine delivery systems (nasal, oral, aerosol, dermal, jet injector delivery) M Liu TAB 9
 930 1000 Immunological basis of mucosal vaccines M Kweon TAB 10
 1000 1015 Coffee break
 1015 1100 Development and GMP production of vaccines R Carbis TAB 11
 1100 1130 Managing intellectual property in vaccine development R Mahoney TAB 12
 1130 1230 Lunch
Chairperson:
 1230 1310 **Lecture on assay development** TBA TAB 13
 1310 1350 Phase I-III pneumococcal conjugate clinical trials: case study P Kilgore TAB 14
 1350 1400 Coffee break
 1400 1500 **IVI laboratory tour** R Carbis
 1530 **Seoul sightseeing**

DAY 3: Wednesday, May 13, 2009**MOVING FROM LICENSING TO INTRODUCTION****Chairperson:**

900	1030	New vaccine evaluation: phase I - III	J Clemens	TAB 15
1030	1045	Coffee break		
1045	1125	Phase 3B studies: demonstration projects	J Clemens	TAB 16
1125	1205	Post-marketing surveillance (Phase 4 studies)	H Margolis	TAB 17
1205	1300	Lunch		

MOVING FROM LICENSING TO INTRODUCTION (2)**Chairperson:**

1300	1330	Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a re-analysis	J Clemens	TAB 18
1330	1430	The changing regulatory environment: the rotavirus vaccine case	I Gust	TAB 19
1430	1445	Coffee break		
1445	1515	Asian regulatory perspective and trends	S Cook	TAB 20
1515	1600	AEFIs and risk communication	F Andre	TAB 21
1600	1615	Coffee break		
1615	1745	Round table discussion: The science, practice, public opinion - a pragmatic approach?	Chaired by F Andre Participants: I Gust, S Cook, J Kuritsky	

DAY 4: Thursday, May 14, 2009**PRODUCT DEVELOPMENT PARTNERSHIPS****Chairperson:**

900	1100	PPPs: 3 models of accelerating the development and introduction of developing country vaccines with local producers/big pharma: Cholera Vaccines (40 mins) Malaria vaccines (40 mins) HPV vaccines (40 mins)	A Lopez K Amfo C Llave	TAB 22 TAB 23 TAB 24
1100	1115	Coffee break		
1115	1145	Negotiating partnerships with the private sector	R Mahoney	TAB 25
1145	1245	Technology transfer Technology transfer: an IVI perspective Development and technology transfer of cost-effective conjugate vaccine against <i>Haemophilus influenzae</i> type b	G Smith M Beurret	TAB 26 TAB 27
1245	1330	Lunch		

PRODUCT DEVELOPMENT PARTNERSHIPS (2)

1330	1500	The Pediatric Dengue Vaccine Initiative and Dengue Vaccines: a case study overview lectures - epidemiology, vaccines, diagnostics and vaccine access	H Margolis, R Mahoney, M Beatty, O Wichmann	TAB 28
1500	1630	Break-out Groups: identification of barriers to evaluation and introduction of dengue vaccines and how to overcome Coffee break (during the breakout session)	H Margolis, J Kuritsky, R Mahoney, M Beatty, O Wichmann	TAB 29
1630	1710	Group discussion: conclusions from breakout groups and discussion	J Kuritsky	

DAY 5: Friday, May 15, 2009

MOVING FROM LICENSURE TO USE

Chairperson:

900	945	Health economics: principles and methods	P Beutels	TAB 30
945	1045	Introduction of vaccines and its economic impact	K Saleh	TAB 31
1045	1100	Coffee break		

Introduction of new vaccines with emphasis in the Asia-Pacific regions:

1100	1130	Hib vaccine introduction in the region	K Edmond	TAB 32
1130	1200	Rotavirus vaccine introduction	T Nelson	TAB 33
1200	1230	Discussion on participant's practical experiences		
1230	1330	Lunch		

Programmatic Considerations:

1330	1400	Financing mechanisms for vaccines: an overview	P Beutels	TAB 34
1400	1430	Financing mechanisms for GAVI eligible countries	D Dunne	TAB 35
1430	1530	Round table discussion	Chaired by P Beutels F Andre, D Dunne, K Saleh	

1530 1545 Coffee break

Chairperson:

1545	1630	Sharing experience: injection safety assessment and adverse event monitoring Discussion on participants' practical experiences	A Amarasinghe	TAB 36
------	------	---	---------------	--------

**Sharing experience: vaccine introduction in GAVI Programs
- cold chain, logistics**

1630	1700	WHO perspective	S Kone	TAB 37
1700	1730	Industry perspective	D Kohl	TAB 38
1730	1820	Discussion on participants' practical experiences		

DAY 6: Saturday, May 16, 2009

SPECIAL LECTURES

Chairperson: J Clemens

900	1030	Keynote closing speech - the future of vaccines and vaccination with special emphasis on avian flu and other pandemics	I Gust	TAB 39
1030	1100	Coffee break		
1100	1200	Closing ceremony	J Clemens	
1200	1400	Lunch		